Acute glaucoma is an inflammatory disease

Article

Acute glaucoma in mice is largely an inflammatory disease, and high intraocular pressure (IOP) causes vision loss by starting an inflammatory response similar to that caused by bacterial infections.

Acute glaucoma in mice is largely an inflammatory disease, and high intraocular pressure (IOP) causes vision loss by starting an inflammatory response similar to that caused by bacterial infections. That's according to researchers at the University of California, San Diego (UCSD) School of Medicine and Sun Yat-sen University in China.

"Our research is the first to show an inflammatory mechanism by which high ocular pressure causes vision loss in acute glaucoma patients," said co-senior author Professor Kang Zhang, MD, PhD, a professor of ophthalmology at UCSD.

The findings were published in the Proceedings of the National Academy of Sciences.

In the study, the investigators showed that a rapid, sustained large increase in IOP in mice turns on the TLR4 gene, which activates a protein, caspase-8. This signalling protein, in turn, triggers the production of inflammatory proteins that normally help mammals fight microbial infections.

"This immune response is a double-edge sword because, while these proteins protect us from infection in a normal situation, they stimulate apoptosis in retinal cells in cases of acute glaucoma," said Prof. Zhang, who is also a staff physician at the Veterans Affairs San Diego Healthcare System.

To further confirm the mechanism linking high IOP to retinal damage, the researchers showed that they could slow retinal cell death in mice with acute glaucoma by suppressing either the TLR4 gene or caspace-8 protein. The latter is particularly significant because caspace-8 inhibitors are being tested in clinical trials of potential cancer and stroke treatments.

"By injecting these inhibitors into the eyes of acute glaucoma patients, it may be possible to evaluate and bring them vision-sparing treatments more quickly," said paper co-author Professor Robert N. Weinreb, MD, chairman and Distinguished Professor of Ophthalmology at UCSD.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.